Global X Copper Miners ETF vs Revvity Inc — how do they compare? Global X Copper Miners ETF trades at $85.75 (market cap $7.10B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.4× Global X Copper Miners ETF's market cap, and Revvity Inc pays a 0.18% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Revvity Inc for 12 Days on average.
| COPX | RVTY | |
|---|---|---|
Market Cap | $7.10B | $16.98B |
Volume | 2,871,128 | 1,456,900 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $157.36 |
52-Week Low | $57.43 | $82.26 |
Typical Hold Time | 51 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $82.22, down 1.63% amid a bearish technical signal with 17 sell indicators versus 2 buy. The ETF faces pressure from moving averages but maintains neutral oscillator readings. Recent news highlights copper's strategic importance for AI infrastructure, with prices reaching all-time highs near $6.85 per pound, though global surplus concerns temper near-term optimism for miners.
The copper shortage narrative driven by AI electrification offers long-term growth potential, but COPX's 0-8% expected return over 6-12 months reflects cautious sentiment. Key risks include Federal Reserve policy impacts, mining equity underperformance versus copper prices, and global supply dynamics. Investors face a trade-off between operational leverage to copper and miner-specific execution challenges.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →